Switch theme
Sign up to access all valuation multiples
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, and America. Its product pipeline is Neuroscience which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
2000
38
LTM Revenue n/a
LTM EBITDA n/a
$775M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lumosa Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Lumosa Therapeutics achieved revenue of $1.2M and an EBITDA of -$12.9M.
Lumosa Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lumosa Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.7M | $1.2M | XXX | XXX | XXX |
| Gross Profit | $0.4M | $1.3M | XXX | XXX | XXX |
| Gross Margin | 26% | 106% | XXX | XXX | XXX |
| EBITDA | -$6.8M | -$12.9M | XXX | XXX | XXX |
| EBITDA Margin | -398% | -1094% | XXX | XXX | XXX |
| Net Profit | -$14.9M | -$7.2M | XXX | XXX | XXX |
| Net Margin | -869% | -608% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lumosa Therapeutics's stock price is TWD 160 (or $5).
Lumosa Therapeutics has current market cap of TWD 27.0B (or $816M), and EV of TWD 25.7B (or $775M).
See Lumosa Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $775M | $816M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lumosa Therapeutics has market cap of $816M and EV of $775M.
Lumosa Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Lumosa Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lumosa Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $775M | XXX | XXX | XXX |
| EV/Revenue | 655.9x | XXX | XXX | XXX |
| EV/EBITDA | -60.0x | XXX | XXX | XXX |
| P/E | -63.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -86.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLumosa Therapeutics's NTM/LTM revenue growth is n/a
Lumosa Therapeutics's revenue per employee for the last fiscal year averaged $31K, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Lumosa Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lumosa Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lumosa Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -31% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1094% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 89% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $31K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 88% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 825% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 957% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lumosa Therapeutics acquired XXX companies to date.
Last acquisition by Lumosa Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Lumosa Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lumosa Therapeutics founded? | Lumosa Therapeutics was founded in 2000. |
| Where is Lumosa Therapeutics headquartered? | Lumosa Therapeutics is headquartered in Taiwan. |
| How many employees does Lumosa Therapeutics have? | As of today, Lumosa Therapeutics has 38 employees. |
| Who is the CEO of Lumosa Therapeutics? | Lumosa Therapeutics's CEO is Mr. Jung-Chin Lin. |
| Is Lumosa Therapeutics publicy listed? | Yes, Lumosa Therapeutics is a public company listed on ROCO. |
| What is the stock symbol of Lumosa Therapeutics? | Lumosa Therapeutics trades under 6535 ticker. |
| When did Lumosa Therapeutics go public? | Lumosa Therapeutics went public in 2015. |
| Who are competitors of Lumosa Therapeutics? | Similar companies to Lumosa Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lumosa Therapeutics? | Lumosa Therapeutics's current market cap is $816M |
| What is the current revenue growth of Lumosa Therapeutics? | Lumosa Therapeutics revenue growth between 2023 and 2024 was -31%. |
| Is Lumosa Therapeutics profitable? | Yes, Lumosa Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
